IVIG Vital Sign Monitoring During Infusion
Monitor vital signs every 30 minutes during the IVIG infusion, then hourly for 4 hours post-infusion, followed by routine monitoring every 4-6 hours for up to 24 hours after completion. 1
Monitoring Schedule During Infusion
Initial Infusion Period (First 30 Minutes)
- Continuous vital sign monitoring during the first 10 minutes is essential, as most immediate infusion reactions occur during this critical window 2
- Check vital signs every 30 minutes throughout the entire infusion 1
- The infusion should begin at a slow rate of 0.01 mL/kg/min (0.5 mg/kg/min) and may be gradually increased after the first 30 minutes if well-tolerated 2, 3
Post-Infusion Monitoring
- Continue vital sign checks hourly (±15 minutes) for 4 hours after infusion completion 1
- Then monitor routinely every 4-6 hours for up to approximately 24 hours post-infusion, unless clinical status indicates more frequent assessment 1
Specific Vital Signs to Monitor
Monitor the following parameters throughout the infusion: 3
- Blood pressure (both systolic and diastolic)
- Heart rate/pulse
- Respiratory rate
- Temperature
- Oxygen saturation (maintain >92%; provide supplemental O₂ at 2-3 L/min if needed) 4
Critical Thresholds Requiring Physician Notification
Call the physician immediately if any of the following occur: 4
- Systolic BP >185 mmHg or <110 mmHg
- Diastolic BP >105 mmHg or <60 mmHg
- Pulse <50 or >110 beats per minute
- Respirations >24 per minute
- Temperature >99.6°F (37.6°C)
- Worsening neurological symptoms or decline in status
Management of Abnormal Vital Signs
If Adverse Reactions Occur
- Stop the infusion immediately while maintaining IV access with normal saline 2
- Monitor for at least 15 minutes after stopping 2
- If symptoms subside promptly, the infusion may be resumed at a lower rate (50% of initial rate) that is comfortable for the patient 3
For Mild Reactions (Flushing, Pruritus, Urticaria)
- Most are self-limiting and resolve within 15 minutes of stopping the infusion 2
- After resolution, restart at 50% of the previous rate 2
For Moderate to Severe Reactions
- Cease infusion while maintaining IV access 2
- If symptoms persist after 15 minutes, administer hydrocortisone 200 mg IV 2
- Give ondansetron 4-8 mg IV for nausea 2
- Use second-generation antihistamines (cetirizine 10 mg IV/PO or loratadine 10 mg PO) for urticaria 2
- For anaphylaxis, give epinephrine 0.3 mg IM immediately 2
High-Risk Patients Requiring Closer Monitoring
Patients with the following conditions require more intensive vital sign monitoring: 3, 5, 6
- Pre-existing renal insufficiency or diabetes mellitus
- Age >65 years
- Volume depletion or sepsis
- Paraproteinemia or hyperviscosity
- History of cardiovascular disease or thromboembolic events
- Patients receiving nephrotoxic medications
- Advanced age, prolonged immobilization, or hypercoagulable conditions
For these high-risk patients, administer IVIG at the minimum dose and slowest infusion rate practicable 3
Common Pitfalls to Avoid
- Do not assume subsequent infusions are safe without monitoring: While some institutions reduce monitoring frequency after the first dose if no reactions occur 7, guideline-based practice emphasizes consistent vital sign monitoring throughout treatment 1, 2
- Avoid rapid infusion rates in high-risk patients: Slow infusion rates prevent renal failure, thromboembolic events, and aseptic meningitis 5, 6
- Do not overlook cardiovascular assessment: Evaluate baseline cardiovascular risk before IVIG administration, as acute myocardial infarction has been reported during infusion in patients with known ischemic heart disease 8
- Ensure adequate hydration: Volume depletion significantly increases the risk of renal complications and thrombotic events 3, 5, 6
Special Considerations for Specific Conditions
For Guillain-Barré Syndrome
- Frequent pulmonary function assessment is critical due to risk of respiratory muscle weakness 9
- Daily neurologic review is essential 9
- Monitor for concurrent autonomic dysfunction 9